Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | CFTR | P13569 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ILK | Q13418 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529864 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL2900514 | 0.90 | KDM4E (0.59) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL2080318 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL30221910 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL29813036 | 0.90 | KDM4E (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL24338831 | 0.87 | GAA (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL19833958 | 0.87 | GAA (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL31430590 | 0.87 | GAA (0.50) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL19175223 | 0.87 | KDM4E (0.47) | KDM4EALDH1A1GAAHSD17B10CFTR | |
| SCHEMBL12164839 | 0.87 | KDM4E (0.47) | KDM4EALDH1A1GAAHSD17B10CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024117179-A1 | KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | ALIVEXIS, INC. (JP) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024043741-A1 | AUTOTAXIN INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 | 2024-02-29 | — | — | WO | disclosed |
| US-20220227762-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2022-07-21 | — | — | US | disclosed |
| CN-113891880-A | Amide substituted imidazo compounds as selective inhibitors of indoleamine 2, 3-dioxygenase | 百济神州有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2020233677-A1 | PROCESS FOR PREPARING AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS | BEIGENE (BEIJING) CO., LTD. (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020233676-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES | BEIGENE, LTD. (KY) | 2020-11-26 | — | — | WO | disclosed |
| EP-3294715-B1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2020-05-06 | — | — | EP | disclosed |
| EP-3294715-B1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2020-05-06 | — | — | EP | disclosed |
| US-20180110755-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2018-04-26 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110755-A1 | BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC6, HDAC1, HDAC11 | KDM4E 1211/4885ALDH1A1 448/4885GAA 138/4885 |
| US-20120232056-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | KDM4E 3115/4885ALDH1A1 3714/4885GAA 306/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | KDM4E 2432/4885ALDH1A1 2293/4885GAA 1581/4885 |
| US-20220227762-A1 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO1, IDO2, AADAC | KDM4E 491/4885ALDH1A1 604/4885GAA 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.